On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) opened higher 1.09% from the last session, before settling in for the closing price of $39.51. Price fluctuations for IONS have ranged from $23.95 to $52.34 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -2.97% at the time writing. With a float of $155.28 million, this company’s outstanding shares have now reached $159.04 million.
In an organization with 1069 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.75%, operating margin of -65.85%, and the pretax margin is -64.7%.
Ionis Pharmaceuticals Inc (IONS) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ionis Pharmaceuticals Inc is 2.44%, while institutional ownership is 104.18%. The most recent insider transaction that took place on May 01 ’25, was worth 477,900. In this transaction Director of this company bought 15,000 shares at a rate of $31.86, taking the stock ownership to the 50,219 shares. Before that another transaction happened on Apr 16 ’25, when Company’s EVP, Corp and Development Ops sold 680 for $28.37, making the entire transaction worth $19,292. This insider now owns 56,660 shares in total.
Ionis Pharmaceuticals Inc (IONS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -2.97% per share during the next fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
Check out the current performance indicators for Ionis Pharmaceuticals Inc (IONS). In the past quarter, the stock posted a quick ratio of 9.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.98, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -3.17 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Let’s dig in a bit further. During the last 5-days, its volume was 2.24 million. That was better than the volume of 1.7 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 82.79%.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 94.78%, which indicates a significant increase from 85.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.06% in the past 14 days, which was lower than the 43.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.16, while its 200-day Moving Average is $34.83. However, in the short run, Ionis Pharmaceuticals Inc’s stock first resistance to watch stands at $40.60. Second resistance stands at $41.26. The third major resistance level sits at $41.70. If the price goes on to break the first support level at $39.50, it is likely to go to the next support level at $39.06. Assuming the price breaks the second support level, the third support level stands at $38.40.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Key Stats
There are currently 159,159K shares outstanding in the company with a market cap of 6.36 billion. Presently, the company’s annual sales total 705,140 K according to its annual income of -453,900 K. Last quarter, the company’s sales amounted to 131,610 K and its income totaled -146,940 K.
